HUTCHMED to Present Key Clinical Data at 2026 ASCO Annual Meeting
Overview
HUTCHMED (China) Limited, a leading biopharmaceutical company focused on oncology and immunology, has announced that it will present new and updated clinical data for several of its innovative therapies at the prestigious 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29 to June 2, 2026, in Chicago, USA.
Key Highlights for Investors
- Pivotal Phase II Study of Savolitinib in MET-Amplified Gastric Cancer:
- The company will present pivotal data from a Phase II registration study of savolitinib for patients with gastric cancer or gastroesophageal junction adenocarcinoma with MET amplification in China.
- The study met its primary endpoint of objective response rate (ORR) per RECIST 1.1, as assessed by an Independent Review Committee (IRC).
- As of the October 8, 2025, data cut-off, the IRC-assessed ORR was 32.3% (95% CI: 21.2%, 45.1%), exceeding the predefined efficacy threshold.
- Secondary endpoints included:
- Disease Control Rate (DCR): 63.1%
- Median Time to Response (TTR): 1.4 months
- Median Duration of Response (DoR): 9.7 months (95% CI: 3.7, 18.5)
- Median Progression-Free Survival (PFS): 4.0 months (95% CI: 2.6, 5.0)
- These positive results supported a New Drug Application (NDA) submission to China’s National Medical Products Administration (NMPA), which was accepted and granted priority review in December 2025.
- The presentation will be delivered during a rapid oral session at ASCO, highlighting the importance and impact of this data.
- Multiple Studies on Fruquintinib and Surufatinib:
- HUTCHMED and investigators will present additional analyses from key studies such as FRESCO, FRESCO-2, FRUSICA-1, FRUSICA-2, and various investigator-initiated trials on fruquintinib and surufatinib, covering a wide range of solid tumors including colorectal, renal cell, gastric, and ovarian cancers.
- Notable presentations include:
- Fruquintinib’s tumor shrinkage and response depth in metastatic colorectal cancer (mCRC) from global trials FRESCO and FRESCO-2.
- Subgroup and biomarker analyses in renal cell carcinoma, endometrial cancer, and other solid tumors, evaluating combination regimens and predictive factors.
- Investigator-initiated trials examining new combinations and sequencing strategies, including fruquintinib combined with immunotherapies, chemotherapy, and targeted agents in multiple lines of treatment.
- Real-world data from the US on fruquintinib use in refractory mCRC, further supporting its global potential.
- Several promising early-phase studies of surufatinib, including combinations with immunotherapies and chemotherapy in advanced biliary tract, pancreatic, ovarian, and thymic cancers, will also be reported.
- Osimertinib Plus Savolitinib in Lung Cancer:
- New phase 2 data will be published on the combination of osimertinib plus savolitinib in patients with non-small cell lung cancer who are resistant to osimertinib and have low-level MET gene copy number.
Why is this News Potentially Price Sensitive?
- The pivotal Phase II savolitinib data exceeded efficacy thresholds and led to a priority NDA review in China. If approved, this could open a new market and revenue stream for HUTCHMED, especially in the high-need MET-amplified gastric cancer segment.
- The breadth of trials and combination studies being presented at ASCO demonstrates robust clinical activity for HUTCHMED’s pipeline. Positive results in multiple tumor types and geographic regions (China, US, Europe) indicate a strong foundation for future growth.
- Investor attention should focus on the regulatory timelines, the potential for label expansions, and global commercialization opportunities for fruquintinib, savolitinib, and surufatinib.
- The real-world data from the US and new combination regimens may attract attention from partners and increase the likelihood of broader market uptake.
Corporate and Regulatory Updates
- HUTCHMED is now a commercial-stage company with three marketed medicines in China, one of which has global approvals (US, Europe, Japan), reflecting growing international recognition.
- The company cautions that forward-looking statements are subject to risks, including clinical, regulatory, and commercial uncertainties. Investors should monitor future announcements for updates on regulatory decisions and study endpoints.
Leadership and Governance
- The announcement was authorized by the Board, which includes Dr. Dan Eldar (Chairman), Dr. Weiguo Su (CEO/CSO), Mr. Johnny Cheng (Acting CEO/CFO), and other notable executive and non-executive directors.
Conclusion
The release of pivotal clinical data, the potential for regulatory approvals, and the broad scope of HUTCHMED’s clinical development program presented at ASCO 2026 represent significant catalysts that may impact investor sentiment and the company’s valuation in the near term.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult professional advisors before making any investment decisions. The information reflects the latest company announcement as of May 22, 2026, and is subject to change without notice.
HUTCHMED 於2026年ASCO年會發佈重要臨床數據
重點摘要
和黃醫藥（中國）有限公司（HUTCHMED）宣佈，將於2026年5月29日至6月2日在美國芝加哥舉行的美國臨床腫瘤學會（ASCO）年會上，發佈多項自主研發藥物的最新及更新臨床數據。
投資者必須關注的重點
- Savolitinib治療MET基因擴增胃癌的二期註冊研究：
- 研究達到主要終點，客觀緩解率（ORR）為32.3%（95% 置信區間：21.2%-45.1%），超過預設療效門檻。
- 次要終點包括疾病控制率（DCR）63.1%、中位反應時間1.4個月、中位緩解持續期9.7個月（95% CI：3.7-18.5）、中位無進展生存期4.0個月（95% CI：2.6-5.0）。
- 該數據支持新藥申請（NDA）於2025年12月被中國國家藥監局（NMPA）受理並獲優先審評。
- Fruquintinib及Surufatinib多項研究：
- 涵蓋FRESCO、FRESCO-2、FRUSICA-1、FRUSICA-2等研究，以及多項腫瘤類型（大腸癌、腎癌、胃癌、卵巢癌等）的探索性臨床試驗。
- 包括與免疫治療、化療等聯合的新組合療法數據，以及美國的真實世界數據。
- 奧希替尼聯合Savolitinib治療肺癌：
- 將發佈針對奧希替尼耐藥、MET低表達基因複製數的非小細胞肺癌患者的二期研究新數據。
為何這些消息或影響股價？
- 關鍵註冊研究數據超預期，並已獲中國優先審評，倘若獲批，將打開新市場和收入來源。
- 多個品種在多種腫瘤及不同地區積極推進，顯示公司管線具高成長潛力。
- 美國真實世界數據及多組合新療法或吸引合作夥伴，推動國際化進度。
企業及監管動態
- 公司現已在中國有三款上市藥物，首款藥物亦已獲美、歐、日批准，國際認可度持續提升。
- 公司提醒，前瞻性聲明受臨床、監管及商業風險影響，投資者應密切留意未來公告及里程碑進展。
高管及治理
- 董事會由Dr Dan Eldar（主席）、Dr Weiguo Su（行政總裁及首席科學官）、Mr Johnny Cheng（代理CEO及CFO）及其他成員組成。
總結
HUTCHMED於ASCO 2026發佈的樞紐臨床數據及潛在監管進展，或成為影響公司股價的重要催化劑，投資者需密切關注。
免責聲明
本文僅供參考，並不構成任何投資建議。投資者應自行進行盡職調查或諮詢專業顧問。信息截至2026年5月22日，或有變動。
